Blend Labs financials
$1.03−5.50%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $123.6M | $115.8M | $109.5M | $235.2M | $234.5M |
| Gross profit | $91.2M | $83.2M | $76.5M | $89.7M | $116.0M |
| Gross margin | 73.8% | 71.9% | 69.8% | 38.1% | 49.5% |
| Operating income | -$21.7M | -$48.8M | -$143.6M | -$746.2M | -$197.2M |
| Net income | -$25.9M | -$60.5M | -$185.3M | -$768.6M | -$171.3M |
| Net margin | −20.9% | −52.2% | −169.2% | −326.8% | −73.1% |
| Diluted EPS | $-0.10 | $-0.24 | $-0.76 | $-3.28 | $-1.30 |
| EBITDA | -$15.9M | -$40.6M | -$119.1M | -$265.8M | -$178.4M |
| Operating cash flow | $11.5M | -$13.0M | -$127.6M | -$190.4M | -$127.5M |
| Free cash flow | -$81.0K | -$22.8M | -$127.7M | -$192.5M | -$129.4M |
| Diluted shares | 258.9M | 253.9M | 245.2M | 234.2M | 132.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $45.1M | $38.0M | $31.0M | $124.2M | $213.1M |
| Short-term investments | $24.7M | $56.2M | $106.0M | $229.9M | $334.1M |
| Total debt | $0.00 | $0.00 | $138.3M | $216.8M | $213.8M |
| Total assets | $170.0M | $178.1M | $206.1M | $432.8M | $1.11B |
| Total liabilities | $41.0M | $40.4M | $179.1M | $268.8M | $301.9M |
| Shareholders' equity | $129.0M | -$56.4M | -$19.2M | $123.2M | $774.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology